Use of Lactate as a Base in Hemodialysis

Nawab, Zeenat M.; Armstrong, Michael K.; Weissberger, Lynne E.; Ing, Todd S.; Hayashi, James A.; Daugirdas, John T.

doi:10.1159/000167515

Cited by 11 publications

(2 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have been hailed as the LEGOs of the biochemical industry because so many different products can be produced from them . For instance, lactic acid is an excipient to control the pH in kidney dialysis in addition to being a monomer for generating poly(lactide) (PLA) plastics, which are biodegradable and easy to recycle due to their labile ester bonds. Ferulic acid is used as an antioxidant fuel stabilizer in the biofuel industry, , and itaconic acid − is used in the manufacturing of plexiglass.…”

Section: Introductionmentioning

confidence: 99%

Integrated Ion-Exchange Membrane Resin Wafer Assemblies for Aromatic Organic Acid Separations Using Electrodeionization

Jordan

Kokoszka

Dona

et al. 2023

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

Aromatic acids, such as p-coumaric acid, are valuable chemical intermediates that are used in the specialty chemical industries because they are precursors to phenylpropanoid compounds. The separation of p-coumaric acid from fermentation broths is a critical step in the biochemical production process and more broadly the circular carbon economy. Electrodeionization (EDI) has been applied toward separations of low-carbon chain acids, but purifying p-coumaric acid has been challenging due to fouling and irreversible binding with ion-exchange membranes and resins. Here, we report a new membrane wafer assembly (MWA) consisting of laminated ion exchange membranes to porous ionomer-binder resin wafers for EDI. The MWAs in an EDI stack showed a 7-fold increase in p-coumaric acid capture while also using 70% less specific energy consumption when benchmarked against state-of-the-art resin wafer EDI modules. The more efficient p-coumaric acid recovery was ascribed to (i) the 38% reduction in interfacial transport resistance between the membrane and resin wafer and (ii) using imidazolium anion exchange membranes and ionomer binders in the MWA. MD simulations revealed enhanced transport rates for p-coumarate in imidazolium ionomers through π–π interactions. Adopting the new MWA significantly reduced the amount of ion-exchange membranes in EDI and may lead to drastic capital cost savings.

show abstract

Section: Introductionmentioning

confidence: 99%

Integrated Ion-Exchange Membrane Resin Wafer Assemblies for Aromatic Organic Acid Separations Using Electrodeionization

Jordan

Kokoszka

Dona

et al. 2023

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

show abstract

“…We began feasibility studies in patients using DLlactate as a dialysis solution base. We found that a dialysis solution containing 40 mM DL-lactate resulted in insufficient correction of acidosis ( 13,14). A reduction in symptoms with lactate was not found erans Administration Hospital, Hines, IL 60141,…”

mentioning

confidence: 95%

An Alternate Base for Hemodialysis: The Promise of l‐Lactate

Daugirdas

Dalal

Ing

1989

Seminars in Dialysis

Self Cite

View full text Add to dashboard Cite

Acetate dialysis solution, especially when used in a high-efficiency dialysis setting, has been associated with hypotension and with symptoms such as nausea, vomiting, and fatigue (1, 2). At present, bicarbonate is the dialysis solution base of choice in highefficiency dialysis. Bicarbonate, however, has prob lems as well, such as the requirement for a relatively complex dual concentrate delivery system adding to the cost of dialysis. In addition, the danger of bacterial contamination exists with bicarbonate concentrate solutions (3, 4).The thinking of the dialysis community with regard to potential bases has been largely bipolar: the choice is either acetate or bicarbonate. However, it has long been recognized that bicarbonate-generating compounds other than acetate are available. Liang and Lowenstein ( 5 ) found that the infusion of pyruvate into dogs was associated with less cardiovascular effects than that of acetate. Wathen et al. (6) demonstrated the bicarbonate-generating ability of pyruvate and m-lactate infused into anesthetized dogs while Gonzalez et al. (7) made similar observations with intravenous succinate.During the past several years, our group has focused on the possibility of using lactate as a dialysis solution base. Our interest in lactate began with studies of the vasorelaxant effects of various potential bicarbonate-generating bases in isolated vascular tissue. In the rat caudal artery, we found that lactate caused far less vasorelaxation than acetate (8). In other studies, we confirmed that acetate has potent vasodilator (9, 10) and cardiodepressant effects (1 1) at concentrations commonly achieved during dialysis. In conscious dogs, acetate, when used in a dialysis setting, and with plasma acetate levels of only 2 to 3 mM, was associated with a substantial decrease in total peripheral resistance. In fact, in sympathectomized dogs, acetate dialysis, but not ' bicarbonate dialysis, was associated with transient cardiovascular collapse (12). All of these findings suggest that use of alternative agents to acetate may be beneficial.We began feasibility studies in patients using DLlactate as a dialysis solution base. We found that a dialysis solution containing 40 mM DL-lactate resulted in insufficient correction of acidosis ( 13, 14). A reduction in symptoms with lactate was not found in these studies, probably because the control acetate treatments were virtually asymptomatic, as only regular, "low-efficiency" dialysis was examined. We then became concerned about reports that exposure to Dlactate might have adverse neurological consequences (15,16). About the same time, chemical firms began to market biologically derived L-lactate for the same price as DL-lactate. We subsequently did a follow-up study comparing DL-Iactate (20 mM of each isomer) with L-lactate (40 mM) as the sole dialysis solution base. No clinical differences were observed and correction of acidosis was comparable though suboptimal, with both forms of lactate. These data suggested that a lactate concentration higher than 40 mM...

show abstract